Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03317158
Recruitment Status : Recruiting
First Posted : October 23, 2017
Last Update Posted : April 17, 2020
Sponsor:
Collaborators:
AstraZeneca
Hoosier Cancer Research Network
Information provided by (Responsible Party):
Noah Hahn, M.D., Hoosier Cancer Research Network

Tracking Information
First Submitted Date  ICMJE October 12, 2017
First Posted Date  ICMJE October 23, 2017
Last Update Posted Date April 17, 2020
Actual Study Start Date  ICMJE November 21, 2017
Estimated Primary Completion Date September 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 29, 2020)
  • Phase 1: Determine the recommended phase 2 dose (RP2D) from BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients treated with immunotherapy doublet combinations [ Time Frame: 6 months ]
    durvalumab plus BCG, durvalumab plus radiation
  • Phase 2: Determine the 6-month relapse-free survival (RFS) rates of BCG-relapsing or persistent non-muscle invasive bladder cancer (NMIBC) subjects treated with immunotherapy doublet combinations or BCG re-treatment [ Time Frame: 6 months ]
    durvalumab plus BCG, durvalumab plus radiation, BCG monotherapy
Original Primary Outcome Measures  ICMJE
 (submitted: October 17, 2017)
  • Phase 1: Determine the recommended phase 2 dose (RP2D) of immunotherapy doublet combinations [ Time Frame: 6 months ]
    durvalumab plus BCG, durvalumab plus radiation
  • Phase 2: Determine the 6-month relapse-free survival (RFS) rates of BCG-relapsing non-muscle invasive bladder cancer (NMIBC) subjects treated with immunotherapy doublet combinations or BCG re-treatment [ Time Frame: 6 months ]
    durvalumab plus BCG, durvalumab plus radiation, BCG monotherapy
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 29, 2020)
  • Phase 1: Characterize the 6-month relapse-free survival (RFS) rate of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) subjects treated with immunotherapy monotherapy or doublet combinations [ Time Frame: 6 months ]
    durvalumab monotherapy, durvalumab plus BCG, durvalumab plus radiation
  • Assess the safety profile of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) subjects treated with immunotherapy monotherapy or doublet combinations by reporting the highest grade adverse event per patient, as assessed by CTCAE v4.0. [ Time Frame: up to 24 months ]
    durvalumab monotherapy, durvalumab plus BCG, durvalumab plus radiation
  • Phase 2: Determine the 24-month relapse-free survival (RFS) rates of BCG-relapsing or persistent non-muscle invasive bladder cancer (NMIBC) subjects treated with immunotherapy doublet combinations or BCG re-treatment [ Time Frame: up to 24 months ]
    durvalumab plus BCG, durvalumab plus radiation, BCG monotherapy
  • Phase 2: Identify significant associations between 6- and 24-month RFS rates and baseline tumor immunohistochemistry staining patterns of PD-L1 and other relevant mechanism of action targets for each drug studied within each study arm. [ Time Frame: up to 24 months ]
    Determine the relapse-free survival (RFS) rate
  • Phase 2: Determine the 6-month relapse-free survival (RFS) rate of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) subjects treated with durvalumab [ Time Frame: 6 months ]
    Determine the 6 month relapse-free survival (RFS) rate
  • Phase 2: Determine the 24-month relapse-free survival (RFS) rate of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) subjects treated with durvalumab. [ Time Frame: up to 24 months ]
    Determine the 24 month relapse-free survival (RFS) rate
  • Assess the safety profile of subjects treated with immunotherapy monotherapy, doublet combinations or BCG re-treatment by reporting the highest grade adverse event per patient as assessed by CTCAE v4.0. [ Time Frame: up to 24 months ]
    durvalumab plus BCG, durvalumab plus radiation, BCG monotherapy
Original Secondary Outcome Measures  ICMJE
 (submitted: October 17, 2017)
  • Phase 1: Characterize the 6-month relapse-free survival (RFS) rate of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) subjects treated with immunotherapy monotherapy or doublet combinations [ Time Frame: 6 months ]
    durvalumab monotherapy, durvalumab plus BCG, durvalumab plus radiation
  • Assess the safety profile of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) subjects treated with immunotherapy monotherapy or doublet combinations by reporting the highest grade adverse event per patient, as assessed by CTCAE v4.0. [ Time Frame: up to 24 months ]
    durvalumab monotherapy, durvalumab plus BCG, durvalumab plus radiation
  • Phase 2: Determine the 24-month relapse-free survival (RFS) rates of BCG-relapsing non-muscle invasive bladder cancer (NMIBC) subjects treated with immunotherapy doublet combinations or BCG re-treatment [ Time Frame: up to 24 months ]
    durvalumab plus BCG, durvalumab plus radiation, BCG monotherapy
  • Phase 2: Identify significant associations between 6- and 24-month RFS rates and baseline tumor immunohistochemistry staining patterns of PD-L1 and other relevant mechanism of action targets for each drug studied within each study arm. [ Time Frame: up to 24 months ]
    Determine the relapse-free survival (RFS) rate
  • Phase 2: Determine the 6-month relapse-free survival (RFS) rate of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) subjects treated with durvalumab [ Time Frame: 6 months ]
    Determine the 6 month relapse-free survival (RFS) rate
  • Phase 2: Determine the 24-month relapse-free survival (RFS) rate of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) subjects treated with durvalumab. [ Time Frame: up to 24 months ]
    Determine the 24 month relapse-free survival (RFS) rate
  • Assess the safety profile of BCG-relapsing non-muscle invasive bladder cancer subjects treated with immunotherapy monotherapy, doublet combinations or BCG re-treatment by reporting the highest grade adverse event per patient as assessed by CTCAE v4.0. [ Time Frame: up to 24 months ]
    durvalumab plus BCG, durvalumab plus radiation, BCG monotherapy
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder
Official Title  ICMJE PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER - (ADAPT-BLADDER) HCRN GU16-243
Brief Summary A multi-arm multi-stage (MAMS) phase 1/2 study. Phase 1 will be conducted in BCG-unresponsive NMIBC patients to establish the safety of durvalumab monotherapy (cohort 1) and durvalumab in combination with BCG (cohort 2a) and external beam radiation therapy (EBRT) (cohort 2b). Provided safety is demonstrated and recommended phase 2 doses (RP2D) are established in phase 1, the study will proceed to phase 2 testing. Phase 2 will be conducted in the BCG-relapsing or persistent NMIBC population. In phase 2, BCG-relapsing or persistent NMIBC subjects will be randomized between treatment arms examining intravesical BCG in combination with novel immunotherapy agents (durvalumab), novel immunotherapy in combination with radiation (durvalumab + EBRT), or retreatment with intravesical BCG. In addition to providing additional safety data on the combination regimens studied, phase 2 will provide preliminary efficacy profiles for BCG-relapsing or persistent NMIBC subjects with and without CIS treated with each regimen. For regimens demonstrating a tolerable safety profile and encouraging clinical activity in this phase 1/2 design, a randomized phase 3 trial of experimental arm therapy versus re-treatment with intravesical BCG therapy would be considered.
Detailed Description

Patient Assignment in Phase 1

Prior to commencing accrual, each study site will be required to self-identify their site as a site with (EBRT+) or without (EBRT-) the capacity to provide radiation therapy as specified in the durvalumab + EBRT arm. The radiation therapy status of each site will remain fixed throughout the course of the trial. In phase 1 of the protocol, patients will be assigned to study treatment cohorts based on patient slot availability and study site choice of radiation therapy arm participation.

Patient Randomization in Phase 2

In phase 2 of the protocol, subjects registered at self-identified EBRT+ study sites will be randomized 1:1 between all actively accruing study arms while subjects registered at self-identified EBRT- study sites will be randomized 1:1 between all actively accruing study arms except the durvalumab + EBRT arm.

Papillary Subgroup Enrollment Cap

As described further in the Section 12 enrollment in Phase 2 of patients with papillary only (Ta or T1) tumors with no evidence of concurrent CIS within each experimental study arm will be capped to ensure adequate representation of patients with CIS for planned efficacy analyses.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Masking Description:
Open-Label
Primary Purpose: Treatment
Condition  ICMJE
  • Urothelial Carcinoma
  • Bladder Cancer
Intervention  ICMJE
  • Drug: Durvalumab
    Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.
    Other Name: Imfinzi
  • Radiation: External Beam Radiotherapy (EBRT)
    EBRT 6 Gy x 3; Cycle 1 Day 1, 3, and 5
  • Biological: Bacillus Calmette-Guérin (BCG)

    Dose level 0 (starting dose) = Full-dose

    Dose level-1 = 1/3rd-dose BCG. Dose level -1 is expected to be utilized during the phase II portion of the study due to the ongoing and persistent shortage of BCG in the US.

Study Arms  ICMJE
  • Experimental: Phase 1: (cohort 1):
    Durvalumab monotherapy (cohort 1)
    Intervention: Drug: Durvalumab
  • Experimental: Phase 1: (cohort 2a) & (cohort 2b):

    (cohort 2a) - Durvalumab plus BCG

    (cohort 2b) - Durvalumab plus External Beam Radiotherapy (EBRT)

    Interventions:
    • Drug: Durvalumab
    • Radiation: External Beam Radiotherapy (EBRT)
    • Biological: Bacillus Calmette-Guérin (BCG)
  • Experimental: Phase 2: (cohort 2a), (cohort 2b), & (BCG re-treatment)

    (cohort 2a) - Durvalumab plus BCG

    (cohort 2b) - Durvalumab plus External Beam Radiotherapy (EBRT)

    (BCG re-treatment) - Cross-over to Durvalumab Monotherapy

    Interventions:
    • Drug: Durvalumab
    • Radiation: External Beam Radiotherapy (EBRT)
    • Biological: Bacillus Calmette-Guérin (BCG)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 17, 2017)
186
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 1, 2023
Estimated Primary Completion Date September 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria (All Patients):

Subject must meet all of the following applicable criteria to participate in this study:

  • Histologically confirmed non-muscle invasive urothelial carcinoma of the bladder (Ta, T1, or Tis stage) on TURBT obtained within 42 days of registration.
  • ECOG (WHO) performance status 0 or 1
  • Age ≥ 18 years old at time of consent
  • Adequate hematologic, hepatic, and renal function as defined by the following laboratory parameters:

    • White blood cell count (WBC) > 3.0 K/mm^3
    • Absolute neutrophil count (ANC) ≥ 1.5 K/mm^3
    • Platelets ≥ 100 K/mm^3
    • Hemoglobin (Hgb) ≥ 9 g/dL
    • Serum total bilirubin: ≤ 1.5 x ULN
    • ALT and AST ≤ 2.5 x ULN
    • Serum creatinine clearance (CrCl) ≥ 30 mL/min using the Cockcroft-Gault equation, see formula below:

      • CrCl = [140-age (years)] x weight (kg) / [72 x serum Cr (mg/dL)] (if subject is female multiply the above by 0.85)
  • Subjects who give a written informed consent obtained according to local guidelines.

Inclusion Criteria (Phase 1 Only):

  • In addition to the inclusion criteria required of all patients listed above, the following inclusion criteria are also required of patients enrolling to Phase 1 of the study.
  • BCG-unresponsive disease defined by any of the following:

    • Persistent or recurrent CIS with or without the presence of concurrent Ta or T1 tumors within 12 months of completion of adequate BCG therapy
    • Recurrent high-grade Ta or T1 tumors within 6 months of completion of adequate BCG therapy

NOTE: In recognition of the fact that procedure scheduling factors beyond the control of the patient or treating physician may cause unintended delays in disease evaluations, patients with pure papillary tumors (Ta or T1) with no components of CIS with recurrence documented within 9 months of completion of adequate BCG therapy who meet all other eligibility criteria may be considered for enrollment after consultation with the study chair.

  • Persistent T1 high-grade tumors at the first disease evaluation (e.g. 3- month post-treatment evaluation) following an adequate BCG induction course
  • Prostatic urethra involvement of NMIBC

Adequate BCG therapy is defined as at least one of the following:

  • At least 5 of 6 doses of an initial induction BCG course plus at least 2 of 3 doses of maintenance therapy
  • At least 5 of 6 doses of an initial induction BCG course plus at least 2 of 6 doses of a second induction course

NOTE: Patients with concurrent non-muscle invasive tumors (CIS, Ta, T1) in the prostatic urethra and/or concurrent non-invasive tumors (CIS, Ta) in the upper urinary tracts (ureter, renal pelvis) are permitted to enroll in Phase 1 of the study. Patients with concurrent T1 tumors in the upper urinary tracts (ureter, renal pelvis) are not eligible to enroll in Phase 1 of the study. Patients who have met the BCG-unresponsive criteria at any time point in their treatment history are permitted to enroll in Phase 1 of the study regardless of the time frame between their most recent BCG treatment administration and study registration dates.

Inclusion Criteria (Phase 2 Only):

  • In addition to the inclusion criteria required of all patients listed above, the following inclusion criteria are also required of patients enrolling to Phase 2 of the study.

Intermediate or high-risk NMIBC defined according to modified EORTC risk criteria summarized as follows:

  • Low-risk Tumors Initial or recurrent tumor > 12 months after resection with all of the following:

    • Solitary tumor
    • Low-grade
    • < 3 cm
    • No CIS
  • Intermediate-Risk Tumors: All tumors not defined in the two adjacent categories (between the category of low- and high-risk).
  • High-risk Tumors: Any of the following:

    • T1 tumor
    • High-grade
    • CIS
    • Multiple and recurrent and large (> 3 cm) Ta low-grade tumors (all conditions must be met for this point on Ta low-grade tumors).

      • Documented recurrence within 15 months of last exposure to intravesical therapy.
      • Recurrence after 1 prior induction course of intravesical BCG.

        8. BCG-relapsing NMIBC defined as recurrent intermediate- or high-risk NMIBC after achievement of a complete response to initial BCG induction therapy which does not meet any of the BCG-unresponsive criteria outlined in section 3.1.2.

OR

BCG-persistent NMIBC defined as persistent intermediate- or high-risk NMIBC at the first disease evaluation after initial BCG induction therapy (with no intervening achievement of complete response) for which a second course of BCG induction therapy is considered a standard of care (e.g. CIS or high grade Ta tumors) which does not meet any of the BCG-unresponsive criteria outlined in section 3.1.2.

NOTE: Patients who have received additional non-BCG based intravesical therapies (e.g. chemotherapy, non-BCG investigational agents) are eligible provided they have received only 1 prior course of BCG induction therapy and satisfy the above BCG-relapsing or BCG-persistent definitions.

Inclusion Criteria (Phase 2 Patients with Persistent or Relapsed NMIBC who Cross-Over to Durvalumab Only):

  • In addition to the inclusion criteria described of all patients listed above, the following inclusion criteria are also required of patients originally enrolled in Phase 2 of the study who are noted to have NMIBC in follow up and opt to cross-over to durvalumab monotherapy.

    • Subjects with BCG-unresponsive disease defined by any of the following:

      • Prior treatment with 2 or more adequate courses of BCG (at least 5 of 6 induction installations and at least 2 of 3 maintenance installations for subjects on maintenance therapy).
      • Persistent T1 high-grade disease at the initial 3-month cystoscopy/TURBT assessment in subjects who received 5 of 6 inductions BCG installations.
      • Relapsed NMIBC within 6 months of last exposure to BCG
      • Prostatic urethra involvement of NMIBC

Primary Exclusion Criteria:

Exclusion Criteria (All Patients):

  • Subjects with muscle-invasive (i.e. T2, T3, T4), locally advanced unresectable, or metastatic urothelial carcinoma as assessed on baseline radiographic imaging obtained within 28 days prior to study registration. The required radiographic imaging includes:

    • Abdomen/Pelvis - CT scan
    • Chest - chest x-ray or CT scan
  • Subjects with another active second malignancy other than non-melanoma skin cancers and biochemical relapsed prostate cancer. Subjects that have completed all necessary therapy and are considered to be at less than 30% risk of relapse are not considered to have an active second malignancy and are eligible for enrollment.
  • Subjects who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, and monoclonal antibodies ≤ 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy.
  • Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria:

    • Patients with Grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the sponsor-investigator.
    • Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the sponsor-investigator.
  • Subjects who have received prior therapy with PD-1 or PD-L1 directed agents.
  • Subjects who have had any prior radiation to the prostate or pelvis.
  • Subjects who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury ≤ 4 weeks prior to starting study drug, or subjects who have had minor procedures (i.e. TURBT), percutaneous biopsies or placement of vascular access device ≤ 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury.
  • Subjects with any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study:

    • Clinically significant cardiac diseases, including any of the following:

      • History or presence of serious uncontrolled ventricular arrhythmias.
      • Clinically significant resting bradycardia.
      • Any of the following within 3 months prior to starting study drug: myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Pulmonary Embolism (PE).
      • Uncontrolled hypertension defined by a SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg, with or without anti-hypertensive medication(s).
    • Cirrhosis
    • Active Infection (includes chronic active and chronic persistent).

      • Tuberculosis
      • Hepatitis B (known positive HBV surface antigen (HbsAg). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HbsAg) are eligible.
      • Hepatitis C. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
      • Known diagnosis of human immunodeficiency virus (HIV/positive HIV 1/2 antibodies) infection (HIV testing is not mandatory).
    • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:

      • Patients with vitiligo or alopecia.
      • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
      • Any chronic skin condition that does not require systemic therapy.
      • Patients without active disease in the last 5 years may be included but only after consultation with the study physician.
      • Patients with celiac disease controlled by diet alone.
    • Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol.
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection).
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent.
    • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
    • Usage of non-steroidal anti-inflammatory medications (NSAIDS) for the treatment of osteoarthritis and uric acid synthesis inhibitors for the treatment of gout are permitted.
  • Pregnant or breast-feeding women. Women of child-bearing potential must have a negative urine or serum test ≤ 14 days prior to starting study drug.
  • Women of child-bearing potential, who are biologically able to conceive, and not employing two forms of highly effective contraception or abstinence. Highly effective contraception or abstinence must be used from the time of informed consent, throughout the trial and up to 180 days after the last dose of durvalumab (e.g. male condom with spermicidal; diaphragm with spermicide; intra-uterine device). Women of child-bearing potential are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    • Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
    • Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
  • Fertile males not willing to use contraception or abstinence, as stated above. Contraception or abstinence must be followed from screening through 180 days after receipt of the final dose of durvalumab therapy.
  • Subjects unwilling or unable to comply with the protocol.
  • Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.
  • Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

Exclusion Criteria (Phase 1 Only):

  • In Phase 1 of the study, there are no additional exclusion criteria beyond those described of all patients in the section listed above.

Exclusion Criteria (Phase 2 Only):

  • In addition to the exclusion criteria described of all patients listed above, the following exclusion criteria apply to patients enrolling to Phase 2 of the study.
  • Subjects with BCG-unresponsive disease defined by any of the following:

    • Prior treatment with 2 or more adequate courses of BCG (at least 5 of 6 induction installations and at least 2 of 3 maintenance installations for subjects on maintenance therapy).
    • Persistent T1 high-grade disease at the initial 3-month cystoscopy/TURBT assessment in subjects who received 5 of 6 inductions BCG installations.
    • Relapsed NMIBC within 6 months of last exposure to BCG.
    • Prostatic urethra involvement of NMIBC.
  • Subjects with concurrent upper urinary tract (i.e. ureter, renal pelvis) non-invasive urothelial carcinoma.

Exclusion Criteria (Phase 2 Patients with Persistent or Relapsed NMIBC who Cross-Over to Durvalumab Only):

  • In addition to the exclusion criteria described of all patients listed above, the following exclusion criteria apply to patients enrolling to the cross-over to durvalumab portion of the Phase 2 study.

    • Subjects with concurrent upper urinary tract (i.e. ureter, renal pelvis) non-invasive urothelial carcinoma.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Robyn Lillie, RN 317.634.5842 ext 60 rlillie@hoosiercancer.org
Contact: Noah M. Hahn, MD 443.287.0553 nhahn4@jhmi.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03317158
Other Study ID Numbers  ICMJE HCRN GU16-243
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Noah Hahn, M.D., Hoosier Cancer Research Network
Study Sponsor  ICMJE Noah Hahn, M.D.
Collaborators  ICMJE
  • AstraZeneca
  • Hoosier Cancer Research Network
Investigators  ICMJE
Study Chair: Noah M. Hahn, MD Hoosier Cancer Research Network
PRS Account Hoosier Cancer Research Network
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP